JAN stock holds its listing and operating story in view

Published on 09/23/2026 at 09:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JAN stock is tied to opioid-use disorder treatment and digital health activity in 2026. Its Nasdaq listing gives investors a defined market reference.

JAN, US47035L1026, Illustration mit AI erstellt.

JanOne Inc. (US47035L1026) remains a Nasdaq-listed healthcare company focused on opioid-use disorder treatment and related digital health activities. On September 23, 2026, the available market record did not provide a substantiated JAN quote, market capitalization, volume, or daily percentage change that can be used as a reference figure.

Healthcare remains the central theme

JanOne's investment case is linked to the development and commercialization of treatments and technologies addressing opioid-use disorder. The company also operates within the broader digital health and life-sciences field, making regulatory progress, financing capacity, and commercial execution material factors for the stock.

Numbers require a dated report

The latest financial figures must be tied to a clearly identified quarterly, half-year, or fiscal-year reporting period. No such period-specific revenue, earnings, margin, guidance, or cash-flow figure is included here, so the article does not assign an undated fundamental value to JanOne.

Nasdaq listing defines the reference

For US-listed JanOne, Nasdaq and USD are the relevant venue and currency framework. The company identity is anchored by ISIN US47035L1026, while the stock narrative remains dependent on a dated quotation and a period-specific financial update.